S&P 500   3,958.50 (-0.13%)
DOW   33,680.59 (-0.30%)
QQQ   284.22 (+0.13%)
AAPL   143.87 (+0.86%)
MSFT   246.83 (-0.23%)
META   116.64 (+1.14%)
GOOGL   93.38 (-0.35%)
AMZN   89.47 (-0.97%)
TSLA   180.95 (+4.33%)
NVDA   173.06 (+0.80%)
NIO   12.80 (-4.55%)
BABA   91.88 (-2.43%)
AMD   69.50 (-1.38%)
T   19.20 (+0.42%)
MU   55.37 (+0.31%)
CGC   2.91 (-5.83%)
F   13.22 (+0.76%)
GE   82.32 (-1.57%)
DIS   93.93 (+1.49%)
AMC   5.88 (-3.13%)
PYPL   74.04 (-0.24%)
PFE   51.98 (+0.39%)
NFLX   324.46 (+4.58%)
S&P 500   3,958.50 (-0.13%)
DOW   33,680.59 (-0.30%)
QQQ   284.22 (+0.13%)
AAPL   143.87 (+0.86%)
MSFT   246.83 (-0.23%)
META   116.64 (+1.14%)
GOOGL   93.38 (-0.35%)
AMZN   89.47 (-0.97%)
TSLA   180.95 (+4.33%)
NVDA   173.06 (+0.80%)
NIO   12.80 (-4.55%)
BABA   91.88 (-2.43%)
AMD   69.50 (-1.38%)
T   19.20 (+0.42%)
MU   55.37 (+0.31%)
CGC   2.91 (-5.83%)
F   13.22 (+0.76%)
GE   82.32 (-1.57%)
DIS   93.93 (+1.49%)
AMC   5.88 (-3.13%)
PYPL   74.04 (-0.24%)
PFE   51.98 (+0.39%)
NFLX   324.46 (+4.58%)
S&P 500   3,958.50 (-0.13%)
DOW   33,680.59 (-0.30%)
QQQ   284.22 (+0.13%)
AAPL   143.87 (+0.86%)
MSFT   246.83 (-0.23%)
META   116.64 (+1.14%)
GOOGL   93.38 (-0.35%)
AMZN   89.47 (-0.97%)
TSLA   180.95 (+4.33%)
NVDA   173.06 (+0.80%)
NIO   12.80 (-4.55%)
BABA   91.88 (-2.43%)
AMD   69.50 (-1.38%)
T   19.20 (+0.42%)
MU   55.37 (+0.31%)
CGC   2.91 (-5.83%)
F   13.22 (+0.76%)
GE   82.32 (-1.57%)
DIS   93.93 (+1.49%)
AMC   5.88 (-3.13%)
PYPL   74.04 (-0.24%)
PFE   51.98 (+0.39%)
NFLX   324.46 (+4.58%)
S&P 500   3,958.50 (-0.13%)
DOW   33,680.59 (-0.30%)
QQQ   284.22 (+0.13%)
AAPL   143.87 (+0.86%)
MSFT   246.83 (-0.23%)
META   116.64 (+1.14%)
GOOGL   93.38 (-0.35%)
AMZN   89.47 (-0.97%)
TSLA   180.95 (+4.33%)
NVDA   173.06 (+0.80%)
NIO   12.80 (-4.55%)
BABA   91.88 (-2.43%)
AMD   69.50 (-1.38%)
T   19.20 (+0.42%)
MU   55.37 (+0.31%)
CGC   2.91 (-5.83%)
F   13.22 (+0.76%)
GE   82.32 (-1.57%)
DIS   93.93 (+1.49%)
AMC   5.88 (-3.13%)
PYPL   74.04 (-0.24%)
PFE   51.98 (+0.39%)
NFLX   324.46 (+4.58%)
NASDAQ:CYCN

Cyclerion Therapeutics - CYCN News Today

$0.71
+0.07 (+10.81%)
(As of 12/9/2022 11:47 AM ET)
Add
Compare
Today's Range
$0.69
$0.72
50-Day Range
$0.35
$0.95
52-Week Range
$0.35
$2.05
Volume
250 shs
Average Volume
178,264 shs
Market Capitalization
$30.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Get Cyclerion Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.



CYCN Media Mentions By Week

CYCN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CYCN
News Sentiment

0.00

0.44

Average
Medical
News Sentiment

CYCN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CYCN Articles
This Week

0

0

CYCN Articles
Average Week

SourceHeadline
msn.com logoWhy American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday
msn.com - November 23 at 6:48 AM
marketwatch.com logoCyclerion Shares Rise After Spurned Bid for Assets
marketwatch.com - November 22 at 3:45 PM
markets.businessinsider.com logoCyclerion Rejects Unsolicited Proposal To Buy Its Assets
markets.businessinsider.com - November 22 at 10:45 AM
finance.yahoo.com logoCyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
finance.yahoo.com - November 22 at 10:45 AM
finance.yahoo.com logoCyclerion Therapeutics lays off nearly half of workforce
finance.yahoo.com - October 7 at 2:44 PM
reuters.com logoCyclerion Therapeutics Inc
reuters.com - September 9 at 9:14 PM
finance.yahoo.com logoCyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 9 at 9:57 PM
finance.yahoo.com logoCyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results
finance.yahoo.com - August 9 at 4:57 PM
finance.yahoo.com logoIs Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Invest In Growth?
finance.yahoo.com - August 8 at 3:51 PM
msn.com logoRecap Of Thursday's Biotech Catalysts - End of The Day Summary
msn.com - July 28 at 10:39 PM
finance.yahoo.com logoCyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
finance.yahoo.com - July 28 at 7:38 AM
finance.yahoo.com logoCyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies
finance.yahoo.com - June 17 at 5:32 PM
marketwatch.com logoCyclerion Therapeutics Posts Positive Study Data for MELAS Treatment
marketwatch.com - June 10 at 3:59 PM
finance.yahoo.com logoAs Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) drops to US$26m market cap, insiders might rethink their US$2.7m stock purchase earlier this year
finance.yahoo.com - May 11 at 1:01 PM
seekingalpha.com logoCyclerion Therapeutics reports Q1 results
seekingalpha.com - May 4 at 6:27 PM
finance.yahoo.com logoCyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results
finance.yahoo.com - May 4 at 6:26 PM
finance.yahoo.com logoIs Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Deliver On Growth Plans?
finance.yahoo.com - February 27 at 8:39 AM
finance.yahoo.com logoCyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
finance.yahoo.com - February 24 at 6:15 PM
finance.yahoo.com logoCyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration
finance.yahoo.com - February 23 at 11:13 AM
nasdaq.com logoOne Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) insider upped their stake by 67% in the previous year
nasdaq.com - January 27 at 8:46 AM
finance.yahoo.com logoCyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology
finance.yahoo.com - January 26 at 10:28 AM
finance.yahoo.com logoCyclerion Therapeutics, Inc. (NASDAQ:CYCN) insider upped their holding by 67% earlier this year
finance.yahoo.com - November 25 at 8:22 AM
finance.yahoo.com logoCyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
finance.yahoo.com - November 9 at 5:59 PM
finance.yahoo.com logoTruist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside
finance.yahoo.com - October 20 at 8:19 PM
fool.com logoCyclerion Therapeutics Inc(CYCN)
fool.com - September 17 at 12:44 AM
finance.yahoo.com logoCyclerion Therapeutics to Participate in Two Upcoming Investor Conferences
finance.yahoo.com - September 8 at 8:38 AM
msn.com logoWhy Cyclerion Therapeutics Shares Are Moving Today
msn.com - July 23 at 12:51 PM
finance.yahoo.com logoCyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Are Down 31% On Their Shares
finance.yahoo.com - July 12 at 8:28 AM
finance.yahoo.com logoCyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers
finance.yahoo.com - July 9 at 9:54 AM
finance.yahoo.com logoCyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership
finance.yahoo.com - July 8 at 6:29 PM
nasdaq.com logoTuesday 6/8 Insider Buying Report: WSC, CYCN
nasdaq.com - June 8 at 1:04 PM
nasdaq.com logoCyclerion Reaches Licensing Agreement With Akebia For Oral SGC Stimulator Praliciguat
nasdaq.com - June 4 at 12:29 PM
finance.yahoo.com logoCyclerion Therapeutics Announces $18 Million Private Placement
finance.yahoo.com - June 4 at 12:29 PM
finance.yahoo.com logoCyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat
finance.yahoo.com - June 4 at 12:29 PM
finance.yahoo.com logoCyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology
finance.yahoo.com - May 27 at 6:36 PM
finance.yahoo.com logoCyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 25 at 10:16 AM
finance.yahoo.com logoThe CEO & Director of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), Peter Hecht, Just Bought 309% More Shares
finance.yahoo.com - May 9 at 1:26 PM
nasdaq.com logoFriday 5/7 Insider Buying Report: CYCN, WY
nasdaq.com - May 7 at 1:38 PM
nasdaq.com logoStock Alert: Cyclerion Therapeutics Jumps 13% As CEO Raises Stake In Co.
nasdaq.com - May 7 at 1:38 PM
uk.finance.yahoo.com logoCyclerion Therapeutics Inc (CYCN) CEO Peter M Hecht Bought $1.7 million of Shares
uk.finance.yahoo.com - May 7 at 8:36 AM
finance.yahoo.com logoCyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress
finance.yahoo.com - April 27 at 1:41 PM
finance.yahoo.com logoCyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors
finance.yahoo.com - April 26 at 8:22 AM
finance.yahoo.com logoCyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference
finance.yahoo.com - April 21 at 9:38 AM
finance.yahoo.com logoCyclerion Therapeutics to Host Pipeline Update Webinar
finance.yahoo.com - April 20 at 8:41 AM
finance.yahoo.com logoAre Institutions Heavily Invested In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?
finance.yahoo.com - March 22 at 8:57 AM
finance.yahoo.com logoCyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update
finance.yahoo.com - February 25 at 8:14 AM
finance.yahoo.com logoCyclerion Therapeutics Announces Clinical and Scientific Advisory Boards
finance.yahoo.com - January 25 at 8:38 AM
finance.yahoo.com logoHow Much Did Cyclerion Therapeutics'(NASDAQ:CYCN) Shareholders Earn From Share Price Movements Over The Last Year?
finance.yahoo.com - January 21 at 10:30 AM
finance.yahoo.com logoCyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference
finance.yahoo.com - January 4 at 7:30 AM
finance.yahoo.com logoCyclerion Announces Leadership Transitions
finance.yahoo.com - December 21 at 12:23 PM
Get Cyclerion Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:CYCN) was last updated on 12/9/2022 by MarketBeat.com Staff